Last reviewed · How we verify
GSK Biologicals HIV Vaccine 732462 — Competitive Intelligence Brief
phase 2
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
GSK Biologicals HIV Vaccine 732462 (GSK Biologicals HIV Vaccine 732462) — GlaxoSmithKline. This vaccine works by stimulating the body's immune system to produce a specific response against the HIV virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK Biologicals HIV Vaccine 732462 TARGET | GSK Biologicals HIV Vaccine 732462 | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK Biologicals HIV Vaccine 732462 CI watch — RSS
- GSK Biologicals HIV Vaccine 732462 CI watch — Atom
- GSK Biologicals HIV Vaccine 732462 CI watch — JSON
- GSK Biologicals HIV Vaccine 732462 alone — RSS
Cite this brief
Drug Landscape (2026). GSK Biologicals HIV Vaccine 732462 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-biologicals-hiv-vaccine-732462. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab